Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma
1998

Cytotoxic Therapy for Advanced Adrenocortical Carcinoma

Sample size: 18 publication Evidence: low

Author Information

Author(s): R Bonacci, A Gigliotti, E Baudin, N Wion-Barbot, P Emy, M Bonnay, AF Cailleux, I Nakib, M Schlumberger

Primary Institution: Institut Gustave Roussy

Hypothesis

The combination of etoposide and cisplatin will be effective in treating advanced adrenocortical carcinoma.

Conclusion

The combination of etoposide and cisplatin resulted in a 33% overall response rate in patients with advanced adrenocortical carcinoma.

Supporting Evidence

  • A complete response was observed in three cases.
  • A partial response was observed in three cases.
  • Tumour response was noted in three of the six patients with progressive disease during treatment.

Takeaway

Doctors tried a new medicine to help people with a rare type of cancer, and it worked for some of them.

Methodology

18 patients with advanced adrenocortical carcinoma were treated with etoposide and cisplatin every 4 weeks, while monitoring mitotane levels.

Limitations

The study had a small sample size and the response rates were relatively low.

Participant Demographics

Median age was 46 years, with 11 females and 7 males.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication